I'm LongbridgeAI, I can summarize articles.Hong Kong's small-cap equities are displaying widening earnings trajectories as commodity and technology plays gain momentum. Chuangxin Industries Holdings (2788.HK) posted RMB 11.53 billion revenue in the first half of 2026, a 32.4% increase year-over-year, with net profit surging 166.1% to RMB 2.305 billion. The aluminum producer's strategic coal mine acquisition is projected to reduce power costs by 0.05-0.06 yuan per kilowatt-hour, supporting margin expansion.
Shenzhen SDMC Technology (0901.HK) completed its transition to AI-focused operations, with first-half profits climbing 75.9% as fiscal 2025 revenue shifted entirely to AI products. The company received board approval for H-share circulation, converting 136,000 non-tradable shares to enhance market liquidity—a move signaling growing institutional interest in its Physical AI ecosystem.
Contrastingly, China BlueChemical (3983.HK) recorded RMB 2.925 billion revenue in 1H2025, slightly below prior-year levels, while trading below broader market benchmarks. Hua Medicine (2552.HK) emerged as a rare profitable biotech player with RMB 108.7 million in 1H2025 sales, drawing analyst attention to its diabetes drug pipeline.
Pak Tak International (2668.HK) finalized the sale of its target group, eliminating RMB 279 million in guarantee obligations. HK Electric Investments (1723.HK) reported HKD 59.39 billion revenue for 1H2026 (+6.7% YoY), though net profit growth remained muted at 0.2%.
Future Mach (1401.HK) saw profits jump 160% on India-driven sales but faces thematic dislocation concerns. Moon Inc. (2638.HK) underwent board restructuring with share placement delays causing volatility. AIM Vaccine (6660.HK) posted RMB 350.6 million revenue (-31.9% YoY) and RMB 122.8 million net loss in 1H2026, despite Moderna-related sector tailwinds.
